Single-dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis-an updated systematic review and meta-analysis.
Acute gastroenteritis
Adolescents
Children
Ondansetron
Vomit
Journal
European journal of pediatrics
ISSN: 1432-1076
Titre abrégé: Eur J Pediatr
Pays: Germany
ID NLM: 7603873
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
15
01
2020
accepted:
15
04
2020
revised:
12
04
2020
pubmed:
10
5
2020
medline:
24
3
2021
entrez:
9
5
2020
Statut:
ppublish
Résumé
This review aimed to meta-analyze evidence of efficacy and safety of one single dose of ondansetron for vomiting in children and adolescents with acute gastroenteritis. Database searches of MEDLINE (PubMed), Scopus (Elsevier), Cochrane Central Register of Controlled Trials (CENTRAL), and ClinicalTrials.gov up to November 2019 were performed. Only randomized clinical trials versus placebo were considered. Fixed and random effect models were used for the analyses of pooled data. Thirteen randomized clinical trials (2146 patients) were finally included. One single dose of ondansetron showed to produce (1) higher chance of vomiting cessation within 8 h (RR 1.41, 95% CI 1.19-1.68; low-quality evidence); (2) lower chances of oral rehydration therapy failure (RR 0.43, 95% CI 0.34-0.55; high-quality evidence), intravenous hydration needs (RR 0.44, 95% CI 0.34-0.57; high-quality evidence), and hospitalization rates within 8 h (RR 0.49, 95% CI 0.32-0.75; high-quality evidence); and (3) no statistically significant differences in return visits to emergency department (RR 1.14, 95% CI 0.74-1.76; high-quality evidence) compared with placebo. Further studies are necessary to better assess long term efficacy and safety of ondansetron in this context.Conclusions: Mixed evidence was found via few studies about the efficacy and safety of a single dose of ondansetron in the pediatric population.What is known:• Ondansetron use for vomiting in pediatric acute gastroenteritis is increasing worldwide.• Actual convictions come from studies evaluating one and more than one dose of the drug.What is new:• This is the first review to collect data about the effects of one single dose of ondansetron on strong and temporally homogeneous clinical outcomes.• This study supports the use of one dose of ondansetron in pediatric acute gastroenteritis.• Further studies are necessary to assess its long-term efficacy and safety.
Identifiants
pubmed: 32382791
doi: 10.1007/s00431-020-03653-0
pii: 10.1007/s00431-020-03653-0
doi:
Substances chimiques
Antiemetics
0
Ondansetron
4AF302ESOS
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1007-1016Références
Elliot EJ (2007) Acute gastroenteritis in children. BMJ. 334(7583):35–40
doi: 10.1136/bmj.39036.406169.80
Van Damme P, Giaquinto C, Huet F et al (2007) Multicenter prospective study of the burden of rotavirus acute gastroenteritis in Europe, 2004-2005: the REVEAL study. J Infect Dis 195(1):S4–S16
doi: 10.1086/516714
King CK, Glass R, Bresee JS et al (2003) Managing acute gastroenteritis among children. MMWR Recomm Rep 52(RR16):1–16
pubmed: 14627948
Lorgelly PK, Joshi D, Iturriza Gómara M et al (2008) Infantile gastroenteritis in the community: a cost-of-illness study. Epidemiol Infect 136(1):34–43
doi: 10.1017/S0950268807008163
Barker SF, Zomer E, O'Toole J et al (2018) Cost of gastroenteritis in Australia: a healthcare perspective. PLoS One 13(4):e0195759
doi: 10.1371/journal.pone.0195759
Majowicz SE, McNab WB, Sockett P et al (2006) Burden and cost of gastroenteritis in a Canadian community. J Food Prot 69(3):651–659
doi: 10.4315/0362-028X-69.3.651
GlaxoSmithKline, Research Triangle Park. Ondansetron (marketed as Zofran) information. Food and Drug Administration (FDA). https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020103s035_020605s019_020781s019lbl.pdf . Accessed 11 Jul 2019
Guarino A, Ashkenazi S, Gendrel D, Lo Vecchio A, Shamir R, Szajewska H, European Society for Pediatric Gastroenterology, Hepatology, and Nutrition, European Society for Pediatric Infectious Diseases (2014) European Society for Pediatric Gastroenterology, Hepatology, and nutrition/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014. J Pediatr Gastroenterol Nutr 59(1):132–152
doi: 10.1097/MPG.0000000000000375
Fedorowicz Z, Jagannath VA, Carter B (2011) Antiemetics for reducing vomiting related to acute gastroenteritis in children and adolescents. Cochrane Database Syst Rev 9:CD005506
Tomasik E, Ziółkowska E, Kołodziej M, Szajewska H (2016) Systematic review with meta-analysis: ondansetron for vomiting in children with acute gastroenteritis. Aliment Pharmacol Ther 44(5):438–446
doi: 10.1111/apt.13728
Leung AK, Robson WL (2007) Acute gastroenteritis in children; role of anti-emetic medication for gastroenteritis-related vomiting. Pediatr Drugs 9:175–184
doi: 10.2165/00148581-200709030-00006
Li ST, DiGiuseppe D, Christakis DA (2003) Antiemetic use for acute gastroenteritis in children. Arch Pediatr Adolesc Med 157:475–479
doi: 10.1001/archpedi.157.5.475
Freedman SB, Uleryk E, Rumantir M, Finkelstein Y (2014) Ondansetron and the risk of cardiac arrhythmias: a systematic review and postmarketing analysis. Ann Emerg Med 64:19–25
doi: 10.1016/j.annemergmed.2013.10.026
U.S. Food and Drug Administration. FDA drug safety communication: new information regarding QT prolongation with ondansetron (Zofran). https://www.fda.gov/Drugs/DrugSafety/ucm310190.htm . Accessed 11 Jul 2019
Government of Canada. Recalls and Safety Alerts. ZOFRAN (ondansetron) – Association with Changes in Electrical Activity in the Heart – For Health Professionals, October 3, 2012. http://www.healthycanadians.gc.ca/recall-alert-rappel-avis/hc-sc/2012/15080a-eng.php . Accessed 11 Jul 2019
Cheng A (2011) Emergency department use of oral ondansetron for acute gastroenteritis-related vomiting in infants and children. Paediatr Child Health 16(3):177–179
doi: 10.1093/pch/16.3.177
Food and Drug Administration (FDA). https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-abnormal-heart-rhythms-may-be-associated-use-zofran-ondansetron . Accessed Jul 11, 2019
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, Clarke M, Devereaux PJ, Kleijnen J, Moher D (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62(10):e1–e34
doi: 10.1016/j.jclinepi.2009.06.006
Greenhalgh T, Peacock R (2005) Effectiveness and efficiency of search methods in systematic reviews of complex evidence: audit of primary sources. BMJ. 331(7524):1064–1065
doi: 10.1136/bmj.38636.593461.68
Roila F, Del Favero A (1995) Ondansetron clinical pharmacokinetics. Clin Pharmacokinet 29(2):95–109
doi: 10.2165/00003088-199529020-00004
Mondick JT, Johnson BM, Haberer LJ, Sale ME, Adamson PC, Coté CJ, Croop JM, Russo MW, Barrett JS, Hoke JF (2010) Population pharmacokinetics of intravenous ondansetron in oncology and surgical patients aged 1-48 months. Eur J Clin Pharmacol 66(1):77–86
doi: 10.1007/s00228-009-0730-8
Elkomy MH, Sultan P, Carvalho B, Peltz G, Wu M, Clavijo C, Galinkin JL, Drover DR (2015) Ondansetron pharmacokinetics in pregnant women and neonates: towards a new treatment for neonatal abstinence syndrome. Clin Pharmacol Ther 97(2):167–176
doi: 10.1002/cpt.5
Blackwell CP, Harding SM (1989) The clinical pharmacology of ondansetron. Eur J Cancer Clin Oncol 25(Suppl 1):S21–S24 discussion S25–7
pubmed: 2533895
Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. http://handbook.cochrane.org . Updated March 2011. Accessed 20 Jan 2019
Bender R, Lange S (2001) Adjusting for multiple testing--when and how? J Clin Epidemiol 54(4):343–349
doi: 10.1016/S0895-4356(00)00314-0
Guyatt GH, Oxman AD, Schünemann HJ, Tugwell P, Knottnerus A (2011) GRADE guidelines: a new series of articles in the journal of clinical epidemiology. J Clin Epidemiol 64(4):380–382
doi: 10.1016/j.jclinepi.2010.09.011
Rerksuppaphol S, Rerksuppaphol L (2010) Efficacy of intravenous ondansetron to prevent vomiting episodes in acute gastroenteritis: a randomized, double blind, and controlled trial. Pediatr Rep 2:e17
doi: 10.4081/pr.2010.e17
Rang NN, Chanh TQ, My PT, Tien TTM (2019) Single-dose intravenous ondansetron in children with gastroenteritis: a randomized controlled trial. Indian Pediatr 56(6):468–471
doi: 10.1007/s13312-019-1570-y
Golshekan K, Badeli H, Rezaieian S, Mohammadpour H, Hassanzadehrad A (2013) Effect of oral ondansetron on decreasing the vomiting associated with acute gastroenteritis in Iranian children. Iran J Pediatr 23:557–563
pubmed: 24800017
pmcid: 4006506
Yilmaz HL, Yildizdas RD, Sertdemir Y (2010) Clinical trial: oral ondansetron for reducing vomiting secondary to acute gastroenteritis in children – a double-blind randomized study. Aliment Pharmacol Ther 31:82–91
doi: 10.1111/j.1365-2036.2009.04145.x
Hagbom M, Novak D, Ekström M, Khalid Y, Andersson M, Lindh M, Nordgren J, Svensson L (2017) Ondansetron treatment reduces rotavirus symptoms-a randomized double-blinded placebo-controlled trial. PLoS One 12(10):e0186824
doi: 10.1371/journal.pone.0186824
Cubeddu LX, Trujillo LM, Talmaciu I et al (1997) Antiemetic activity of ondansetron in acute gastroenteritis. Aliment Pharmacol Ther 11:185–191
doi: 10.1046/j.1365-2036.1997.97269000.x
Freedman SB, Adler M, Seshadri R, Powell EC (2006) Oral ondansetron for gastroenteritis in a pediatric emergency department. N Engl J Med 354:1698–1705
doi: 10.1056/NEJMoa055119
Ramsook C, Sahagun-Carreon I, Kozinetz CA, Moro-Sutherland D (2002) A randomized clinical trial comparing oral ondansetron with placebo in children with vomiting from acute gastroenteritis. Ann Emerg Med 39:397–403
doi: 10.1067/mem.2002.122706
Danewa AS, Shah D, Batra P, Bhattacharya SK, Gupta P (2016) Oral ondansetron in management of dehydrating diarrhea with vomiting in children aged 3 months to 5 years: a randomized controlled trial. J Pediatr 169:105–109
doi: 10.1016/j.jpeds.2015.10.006
Marchetti F, Bonati M, Maestro A, Zanon D, Rovere F, Arrighini A, Barbi E, Bertolani P, Biban P, da Dalt L, Guala A, Mazzoni E, Pazzaglia A, Perri PF, Reale A, Renna S, Urbino AF, Valletta E, Vitale A, Zangardi T, Clavenna A, Ronfani L, on behalf of the SONDO (Study ONdansetron vs DOmperidone) Investigators (2016) Oral Ondansetron versus domperidone for acute gastroenteritis in pediatric emergency departments: multicenter double blind randomized controlled trial. PLoS One 11(11):e0165441
doi: 10.1371/journal.pone.0165441
Freedman SB, Soofi SB, Willan AR, Williamson-Urquhart S, Ali N, Xie J, Dawoud F, Bhutta ZA (2019) Oral Ondansetron administration to nondehydrated children with diarrhea and associated vomiting in emergency Departments in Pakistan: a randomized controlled trial. Ann Emerg Med 73(3):255–265
doi: 10.1016/j.annemergmed.2018.09.011
Roslund G, Hepps TS, McQuillen KK. The role of oral ondansetron in children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy: a randomized controlled trial. Ann Emerg Med. 2008;52:22–9. Erratum in: Ann Emerg Med. 2008;52:406
Stork CM, Brown KM, Reilly TH, Secreti LL, Brown LH (2006) Emergency department treatment of viral gastritis using intravenous ondansetron or dexamethasone in children. Acad Emerg Med 13:1027–1033
doi: 10.1197/j.aem.2006.05.018
Canziani BC, Uestuener P, Fossali EF, Lava SAG, Bianchetti MG, Agostoni C, Milani GP (2018) Clinical practice: nausea and vomiting in acute gastroenteritis: physiopathology and management. Eur J Pediatr 177:1–5
doi: 10.1007/s00431-017-3006-9
Hoffman RJ, Alansari K (2018) Effect of intravenous ondansetron on QTc interval in children with gastroenteritis. Am J Emerg Med 36(5):754–757
doi: 10.1016/j.ajem.2017.10.004
Trefz FM, Lorch A, Feist M, Sauter-Louis C, Lorenz I (2013) The prevalence and clinical relevance of hyperkalaemia in calves with neonatal diarrhoea. Vet J 195(3):350–356. https://doi.org/10.1016/j.tvjl.2012.07.002
doi: 10.1016/j.tvjl.2012.07.002
pubmed: 22967927
Freedman SB, Steiner MJ, Chan KJ (2010) Oral ondansetron administration in emergency departments to children with gastroenteritis: an economic analysis. PLoS Med 7(10):e1000350